6-K
OKYO Pharma Ltd (OKYO)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-16
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
July2026
CommissionFile Number: 001-41386
OKYOPharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9^th^Floor
107Cheapside
London
EC2V6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATIONCONTAINED IN THIS REPORT ON FORM 6-K
On July 22, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)
| 2 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OKYO Pharma LTD | ||
|---|---|---|
| Date:<br> July 22, 2026 | By: | /s/ Keeren Shah |
| Name: | Keeren<br> Shah | |
| Title: | Chief<br> Financial Officer |
| 3 |
| --- |
EXHIBITINDEX
| Exhibit No. | **** | Description |
|---|---|---|
| 99.1 | News Announcement, dated July 22, 2026 |
| 4 |
| --- |
Exhibit99.1
OKYOPharma Announces Purchase of Shares by Chief Medical Officer
London and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.
AboutOKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visit www.okyopharma.com.
Forfurther inquiries:
OKYOPharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: [email protected]